SCHEMBL4833891

SCHEMBL4833891

COc1ccccc1C(=O)Nc1ccc(N2CN=c3sccc3=C2N)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 12/20 0.54
▸ RAB9A P51151 4/20 0.54
▸ SMN1; SMN2 Q16637 4/20 0.54
▸ NPC1 O15118 2/20 0.54
▸ AHR P35869 1/20 0.54
▸ GFER P55789 1/20 0.54
▸ LMNA P02545 2/20 0.52
▸ TP53 P04637 5/20 0.51
▸ ALDH1A1 P00352 4/20 0.50
▸ HPGD P15428 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ MAPK1 P28482 2/20 0.48
▸ TSHR P16473 1/20 0.48
▸ POLB P06746 1/20 0.47
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ LCK P06239 1/20 0.44
▸ KDR P35968 1/20 0.44
▸ MAPK14 Q16539 1/20 0.44
▸ KCNK3 O14649 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4835290 0.83 RAB9A (0.49) MAPTRAB9ASMN1; SMN2NPC1LMNA
SCHEMBL4828766 0.78 RAB9A (0.47) MAPTRAB9ASMN1; SMN2NPC1LMNA
SCHEMBL4835951 0.76 LMNA (0.44) MAPTSMN1; SMN2LMNAALDH1A1HPGD
SCHEMBL4834603 0.75 BAZ1A (0.41) MAPTSMN1; SMN2NPC1ALDH1A1POLB
SCHEMBL4831024 0.74 TRPV1 (0.50) MAPTSMN1; SMN2NPC1TSHRMEN1
SCHEMBL4833666 0.74 L3MBTL1 (0.47) MAPTRAB9ASMN1; SMN2NPC1TP53
SCHEMBL4833753 0.73 SCN3A (0.51) RAB9ASMN1; SMN2NPC1LMNAALDH1A1
SCHEMBL4831085 0.73 SCN3A (0.51) RAB9ASMN1; SMN2NPC1LMNAALDH1A1
SCHEMBL4831551 0.73 LCK (0.50) MAPTRAB9AALDH1A1HSD17B10KMT2A
SCHEMBL678394 0.71 MAPT (0.69) MAPTRAB9ASMN1; SMN2NPC1AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK MAPT 2499/4885RAB9A 3248/4885SMN1; SMN2 4268/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR MAPT 2424/4885RAB9A 4166/4885SMN1; SMN2 3836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback